LongBio

LongBio, a biopharmaceutical company specializing in biomacromolecule drug development and based in Suzhou, China, has reportedly secured nearly RMB 100 million in a Series B2 financing round. The round was led by Qiming Venture Partners, with the funds earmarked to accelerate the clinical trials of its core programs in China,…